Fineline Cube

Follow:
14682 Articles
Hengrui Wins NMPA Clinical Trial Approval for SHR‑3201 – First‑in‑Class Investigational Therapy Targeting Alzheimer's Disease
CompanyDrug

Hengrui Wins NMPA Clinical Trial Approval for SHR‑3201 – First‑in‑Class Investigational Therapy Targeting Alzheimer’s Disease

Suzhou Zelgen Submits NDA to NMPA for Gecacitinib's Third Indication – Novel JAK inhibitor Targeting Active Ankylosing Spondylitis
CompanyDrug

Suzhou Zelgen Submits NDA to NMPA for Gecacitinib’s Third Indication – Novel JAK inhibitor Targeting Active Ankylosing Spondylitis

Johnson & Johnson Posts Q3 2026 Revenue of USD 25.4 Billion, Raises Full‑Year Guidance – Innovative Medicine Drives 6.0% Operational Growth
Company

Johnson & Johnson Posts Q3 2026 Revenue of USD 25.4 Billion, Raises Full‑Year Guidance – Innovative Medicine Drives 6.0% Operational Growth

Wuhan Hiteck Licenses HT006.2.2 rhNGF Eye Drops to Visara for Ex‑Greater China – Up to USD 111 Million Deal Advances Next‑Generation Neurotrophic Keratitis Therapy
CompanyDeals

Wuhan Hiteck Licenses HT006.2.2 rhNGF Eye Drops to Visara for Ex‑Greater China – Up to USD 111 Million Deal Advances Next‑Generation Neurotrophic Keratitis Therapy

InnoCare's Mesutoclax Wins CDE Approval for Registrational Phase III Trial With Orelabrutinib in Relapsed/Refractory MZL – Fifth Registrational Study for China's First BTD‑Designated BCL2 Inhibitor
CompanyDrug

InnoCare’s Mesutoclax Wins CDE Approval for Registrational Phase III Trial With Orelabrutinib in Relapsed/Refractory MZL – Fifth Registrational Study for China’s First BTD‑Designated BCL2 Inhibitor

Laekna's LAE102 Delivers Promising Weight Loss With Lean Mass Gains in Completed 24‑Week Low‑Dose Monotherapy Cohorts – Selective ActRIIA Antibody Well Tolerated, High‑Dose Cohort Fully Enrolled
CompanyDrug

Laekna’s LAE102 Delivers Promising Weight Loss With Lean Mass Gains in Completed 24‑Week Low‑Dose Monotherapy Cohorts – Selective ActRIIA Antibody Well Tolerated, High‑Dose Cohort Fully Enrolled

CARsgen Doses First Patient in Registrational Phase I Trial of CT0596 – Allogeneic BCMA CAR‑T Built on THANK‑u Plus® Platform Advances Toward Relapsed/Refractory Multiple Myeloma
CompanyDrug

CARsgen Doses First Patient in Registrational Phase I Trial of CT0596 – Allogeneic BCMA CAR‑T Built on THANK‑u Plus® Platform Advances Toward Relapsed/Refractory Multiple Myeloma

Wantai/Innovax Receives NMPA Clinical Trial Approval for Lyophilized Recombinant RSV Vaccine (CHO Cell) – Adjuvant‑Free Pre‑F Protein Candidate Targets Adults Aged 60 and Above
CompanyDrug

Wantai/Innovax Receives NMPA Clinical Trial Approval for Lyophilized Recombinant RSV Vaccine (CHO Cell) – Adjuvant‑Free Pre‑F Protein Candidate Targets Adults Aged 60 and Above

Sansure Biotech's Quadruplex Respiratory Pathogen PCR Kit Wins NMPA Registration – Second Lyophilized Four‑in‑One Test Extends AI‑Driven Respiratory Panel Portfolio to Eight Pathogens
CompanyMedical Device

Sansure Biotech’s Quadruplex Respiratory Pathogen PCR Kit Wins NMPA Registration – Second Lyophilized Four‑in‑One Test Extends AI‑Driven Respiratory Panel Portfolio to Eight Pathogens

Guangdong True Health Medical's Gene‑Edited Pig Liver Perfusion Support Sets 144‑Hour Global Record – World's First Prolonged Xenotransplantation Efficacy Validation in Preclinical Acute Liver Failure Model
Company

Guangdong True Health Medical’s Gene‑Edited Pig Liver Perfusion Support Sets 144‑Hour Global Record – World’s First Prolonged Xenotransplantation Efficacy Validation in Preclinical Acute Liver Failure Model

Roche Inks Exclusive Worldwide License With Rona Therapeutics for ALK7‑Targeting RNAi Candidate – Up to USD 1.16 Billion Deal Advances Genetically Validated Obesity Target via Extrahepatic Delivery
CompanyDeals

Roche Inks Exclusive Worldwide License With Rona Therapeutics for ALK7‑Targeting RNAi Candidate – Up to USD 1.16 Billion Deal Advances Genetically Validated Obesity Target via Extrahepatic Delivery

Sinocelltech's SCT810 Injection Wins NMPA Clearance for Phase I/II Study – Anti‑TFPI Antibody Offers Factor‑Independent Prophylaxis for Hemophilia A and B With or Without Inhibitors
CompanyDrug

Sinocelltech’s SCT810 Injection Wins NMPA Clearance for Phase I/II Study – Anti‑TFPI Antibody Offers Factor‑Independent Prophylaxis for Hemophilia A and B With or Without Inhibitors